Targeting NaPi2b in ovarian cancer

Banerjee, Susana; Drapkin, Ronny; Richardson, Debra L.; Birrer, Michael J.

doi:10.1016/j.ctrv.2022.102489

Cited by 21 publications

(15 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, this study was encouraging regarding the use of LIFA ( 10 ). A careful analysis of the literature review established that NaPi2b fulfils the conditions of an OC biomarker and may serve as a target for therapy in this cancer ( 3 ).…”

Section: Sodium-dependent Phosphate Transport Protein 2b (Napi2b)mentioning

confidence: 99%

Selected markers of ovarian cancer and their relation to targeted therapy (Review)

Markowska,

Kojs,

Twardawa

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Despite advances in surgical treatment techniques and chemotherapy-including anti-angiogenic and immune poly (ADP-ribose) polymerase inhibitors, the 5-year survival rate in ovarian cancer (OC) remains low. The reasons for this are the diagnosis of cancer in advanced clinical stages, chemoresistance and cancer recurrence. New therapeutic approaches are being developed, including the search for new biomarkers that are also targets for targeted therapy. The present review describes new molecular markers with relevance to targeted therapy, which to date have been studied only in experimental research. These include the angiogenic protein angiopoietin-2, the transmembrane glycoprotein ectonucleotide pyrophosphatase/phosphodiesterase 1, the adhesion protein E-cadherin, the TIMP metallopeptidase inhibitor 1 and Kruppel-like factor 7. Drugs affecting cancer stem cells (CSCs) in OC, such as metformin and salinomycin, as well as inhibitors of CSCs markers aldehyde dehydrogenase 1 (with the drug ATRA) and the transcription factor Nanog homeobox (microRNA) are also discussed. A new approach to prevention and possible therapies under investigation such as development of vaccines containing a subpopulation of CD117(+) and CD44(+) stem cells with a promising option for use in women with OC was described.

show abstract

Section: Sodium-dependent Phosphate Transport Protein 2b (Napi2b)mentioning

confidence: 99%

Selected markers of ovarian cancer and their relation to targeted therapy (Review)

Markowska,

Kojs,

Twardawa

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“… 54 Napi2b is thought to play a role in tumorigenesis from dysregulation of phosphate homeostasis in ovarian, lung, and breast cancers. 55 Because of this pathophysiology, Napi2b is an attractive target for ADCs.…”

Section: Napi2b Targeted Therapiesmentioning

confidence: 99%

Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals

McNamara,

Chang,

Goreshnik

et al. 2023

IJWH

View full text Add to dashboard Cite

Antibody drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor surface receptor-targeting antibody with a highly cytotoxic molecule payload. They enable delivery of cytotoxic therapy more directly to tumor cells and minimize delivery to healthy tissues. This review summarizes the existing literature about ADC therapies approved for use in gynecologic malignancies, relevant preclinical studies, as well as ongoing clinical trials.

show abstract

“…As a result, it is of great clinical importance to identify the potential biomarkers and therapeutic targets in metastatic OC [4][5].…”

Section: Introductionmentioning

confidence: 99%

Hsa_circ_0013561 promotes epithelial-mesenchymal transition and tumor progression by regulating ANXA2 via miR-23b-3p in ovarian cancer

Qin

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the most lethal malignancies worldwide and its tumorigenesis and progression are largely unknown. As an important class of endogenous regulatory non-coding RNAs, Circular RNAs play a critical role in various cancers. Our preliminary experiment discovered that hsa_circ_0013561 was aberrantly expressed in OC. However, the underlying mechanism is unclear. The expression of hsa_circ_0013561 in OC cells and tissues was detected by RT-qPCR and fluorescence in situ hybridization. The effects of hsa_circ_0013561 on the proliferation and metastasis of OC were explored by functional experiments such as cell counting kit 8, transwell, and tumor xenograft models. To mechanistically understand the regulatory role of hsa_circ_0013561, bioinformatics analysis, Western blot, luciferase reporter assay, and a series of rescue experiments were applied. We found that the hsa_circ_0013561 expression was elevated in OC cells and tissues, and was correlated with metastasis formation. Downregulation of hsa_circ_0013561 suppressed the proliferation and migration of OC cells both in vitro and in vivo. Regarding the interactions of hsa_circ_0013561, luciferase reporter assay verified that miR-23b-3p and Annexin A2 (ANXA2) were its downstream targets. MiR-23b-3p inhibition or ANXA2 overexpression reversed OC cell proliferation, migration, and epithelial-mesenchymal transition (EMT) post-hsa_circ_0013561 silencing. Moreover, ANXA2 overexpression also reversed OC cell migration, proliferation, and EMT after miR-23b-3p upregulation. Our data suggest that hsa_circ_0013561 increases the expression of ANXA2 through regulating miR-23b-3p competitively, resulting in EMT and metastasis of OC. Thus, hsa_circ_0013561 may serve as a novel oncogenic biomarker for OC progression.

show abstract

Targeting NaPi2b in ovarian cancer

Cited by 21 publications

References 63 publications

Selected markers of ovarian cancer and their relation to targeted therapy (Review)

Selected markers of ovarian cancer and their relation to targeted therapy (Review)

Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals

Hsa_circ_0013561 promotes epithelial-mesenchymal transition and tumor progression by regulating ANXA2 via miR-23b-3p in ovarian cancer

Contact Info

Product

Resources

About